Aster DM Healthcare and Quality Care India Limited (QCIL) have made announcements regarding the progress of the merger, forming one of the top three hospital chains in India, ‘Aster DM Quality Care Limited’, with more than 10,625 beds. The combined entity on a proforma basis showed strong revenue growth of 15% YoY to INR 2,366 crore and a sharp increase of 22% in Operating EBITDA to INR 503 crore in Q3FY26, with improved margins of 21%. The deal is cash neutral and expected to be EPS accretive.
The Financial Deep Dive
The proposed merger of Aster DM Healthcare Limited with Quality Care India Limited (QCIL) is expected to make a strong presence in the Indian healthcare industry, targeting a position among the top three hospital chains in the country. The combined entity, named ‘Aster DM Quality Care Limited’, will make a strong impact with more than 10,625 beds spread across 28 cities, with future plans to expand to around 14,710 beds.
The Numbers:
On a third quarter of Fiscal Year 2026 (Q3FY26) basis, the proforma combined entity reported strong financial performance. The top line grew by a significant 15% year-on-year (YoY) to INR 2,366 crore. Total patient volumes registered a healthy 9% YoY growth to 1.97 million. Operating EBITDA reported strong growth, advancing 22% YoY to INR 503 crore. This was backed by an improvement in EBITDA margins, which expanded to 21% from 20% in Q3FY25, marking strong operational leverage.
On a nine-month basis for FY26 (9MFY26), the combined entity reported revenue of INR 6,913 crore, a 13% YoY increase. Operating EBITDA grew by 20% YoY to INR 1,496 crore, sustaining healthy EBITDA margins at 21.6%.
The standalone performance of Aster DM Healthcare in Q3FY26 also reported encouraging growth, with revenue growing 13% YoY to INR 1,186 crore and EBITDA rising 11% YoY to INR 224 crore.
The Quality:
The deal is designed to be cash neutral for equity shareholders and is expected to be EPS accretive from the first full year of operation. The logic of the deal focuses on scale, improved financial and operating performance, and the achievement of substantial revenue and cost synergies, which are estimated to offer a short-term EBITDA upside potential of 10-15%. The support of global investor Blackstone lends financial strength and strategic support.
Financially, the combined company reported net debt of INR 953 crore and a Return on Capital Employed (RoCE) of 20.7% in Q3FY26. The standalone balance sheet of Aster DM Healthcare reflects an increase in Property, Plant, and Equipment (PPE) and substantial growth in Lease Liabilities as per INDAS116, which is a standard accounting treatment for leases.
Risks & Outlook:
The major risks are linked to the successful amalgamation of the two companies and the achievement of synergy benefits. The amalgamation is an ongoing process, with petitions filed with the National Company Law Tribunal (NCLT) and shareholder meetings scheduled. The fact that the completion of the amalgamation is expected in Q1FY27 will see investors closely watching the execution of the plan. The company has plans for prudent brownfield and greenfield expansion, which will be closely watched by the market as it seeks to leverage its size advantage to achieve further growth and profitability in the competitive healthcare industry.
